http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
-
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
-
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
-
Altimmune to Participate in the Citizens Life Sciences Conference
-
Altimmune to Host Virtual R&D Day on March 13, 2025
-
Altimmune to Participate in the Leerink Global Healthcare Conference
-
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
-
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
-
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025
-
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
-
Altimmune (ALT) Added to Nasdaq Biotechnology Index
-
Altimmune Added to Nasdaq Biotechnology Index
-
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune (ALT) Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease
-
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
-
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
-
Altimmune (ALT) Appoints Greg Weaver as CFO
-
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
-
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Altimmune (ALT) Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide
-
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
-
Altimmune to Participate at Two Upcoming Investor Conferences
-
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
-
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
-
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
-
Altimmune (ALT) Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
-
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
-
Altimmune (ALT) Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
-
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
-
Altimmune (ALT) Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
-
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
-
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
-
Altimmune (ALT) Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease
-
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
-
Altimmune to Participate at Leerink Partners Therapeutics Forum
-
Altimmune (ALT) Announces Passing of CFO Richard Eisenstadt
-
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
-
Altimmune (ALT) Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at ADA
-
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
-
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
-
TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
-
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
-
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
-
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associate
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
